Possible Biological Heterogeneity of Airway Mucus Plugs in a Patient with Asthma
Hiroki Tashiro,Mizuki Nanri,Yuki Kuwahara,Yuki Kurihara,Shinya Kimura,Koichiro Takahashi
DOI: https://doi.org/10.2147/jaa.s499026
2024-12-11
Journal of Asthma and Allergy
Abstract:Hiroki Tashiro, Mizuki Nanri, Yuki Kuwahara, Yuki Kurihara, Shinya Kimura, Koichiro Takahashi Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Saga Prefecture, Japan Correspondence: Hiroki Tashiro, Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, Saga Prefecture, 849-8501, Japan, Tel +81 952 34 2369, Fax + 81 952 34 2017, Email Background: The presence of mucus plugs in the airway is a severe phenotype in patients with asthma; however, the mechanisms and specific treatments are not fully understood. Purpose: To clarify the efficacy of biologics and the mechanisms for mucus plug in patients with asthma. Patients and Methods: A 79-year-old Japanese asthmatic woman with high blood eosinophil and fractional exhaled nitric oxide (FeNO) was pointed massive mucus plugs in airway on chest CT imaging. She was treated with mepolizumab for 3 months; however, those were augmented without improvement of pulmonary function and FeNO. She was switched to dupilumab and, three months later, the mucus plugs were completely disappeared with improvement in pulmonary function, FeNO and asthma-related symptoms. She continues treatment with dupilumab, and her asthma symptoms are stable. Conclusion: Biologics including mepolizumab and dupilumab have been reported to improve mucus plugs in patients with asthma; however, their efficacy might be different depending on the clinical characteristics of patients. Present data remind us of the possibility that, if FeNO levels remain high after treatment with anti-IL-5 antibody in asthma patients with mucus plugs, switching to other biologics, including anti-IL-4Rα antibody, might be considered. Keywords: asthma, biologics, mucus plugs, mechanisms The presence of mucus plugs in the airway, which are detected as high attenuation structures on computed tomography (CT) on the mediastinal window setting, is a severe phenotype in patients with asthma, whose particular characteristic is eosinophilic airway inflammation called "type 2 inflammation". 1 Mucus plugs contribute to decreased pulmonary function, and they might be related to mortality in patients with asthma 2,3 ; however, the mechanisms and specific treatments are not fully understood. Currently, several biologics including anti-immunoglobulin E (IgE), anti-interleukin (IL)-5, anti-IL-5 receptor alpha (IL-5Rα), anti-IL-4 receptor alpha (IL-4Rα), and anti-thymic stromal lymphopoietin (TSLP) antibodies are clinically available for treating patients with severe uncontrolled asthma, and the efficacies are greater for patients with eosinophilic airway inflammation. 4 Additionally, the treatment efficacy of each biologic allows us to understand the biological phenotypes of patients with severe eosinophilic asthma. In this report, the case of an asthma patient with mucus plugs treated sequentially with anti-IL-5 antibody and anti-IL-4Rα antibody, showing different effects for mucus plugs in different anatomical locations, which suggests the biological heterogeneity of airway mucus plugs in patients with asthma, is presented. A 79-year-old Japanese woman who had cataract, glaucoma, and allergic rhinitis consulted our hospital for increased cough and sputum. She had been diagnosed as having asthma 2 months earlier and was treated with a medium dose of inhaled corticosteroid (ICS), a long-acting β2 adrenergic agonist, and a leukotriene receptor antagonist. She had no history of chronic sinusitis, alcohol abuse, smoking and allergic reaction to foods and drugs. On physical examination, she had productive cough and wheezes on both sides of the chest without fever, hypoxia, or skin rash. Her chest X-ray showed consolidation in the middle central and lower peripheral fields of the right lung (Figure 1A). Chest CT showed a funicular shadow in the right upper lobe and consolidation in the right middle lobe in the lung window setting, with high attenuation structures in the mediastinal window setting, indicating mucus plugs, in the B3 and B4 bronchi (Figure 1B–E). On laboratory examination, the white blood cell count was 6600/μL, with 20% eosinophils (1320/μL), total IgE was 232 IU/mL without positive findings for any specific IgE levels including Aspergillus and Alternaria. The asthma control test (ACT) score was 17 points, and on pulmonary function testing, vital capacity (VC) was 1930 mL, %VC was 78.8%, forced vital capacity was 1800 mL, %FVC was 75.9%, forced expiratory volume in 1 second (FEV1) was 1330 mL, %FEV1 was 73.5% and fractional exhaled nitric oxide (FeNO) was 66 ppb. Considering the adverse effects of systemic corticosteroid treatment and he -Abstract Truncated-
immunology,allergy,respiratory system